anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to methods for assessing swallowing motor function in a subject. The methods rely on obtaining intraluminal impedance and pressure measurements from the pharynx and/or esophagus of the subject during clearance of a bolus from the mouth and/or throat of the subject. The intraluminal impedance and pressure measurements are combined to derive a value for one or more pressure-flow variables in the pharynx and/or the esophagus of the subject. The value of the one or more pressure-flow variables is compared to a predetermined pharyngeal and/or esophageal reference value for the one or more pressure-flow variables in order to provide an assessment of swallowing motor function in the subject. The intraluminal impedance and pressure measurements can also be combined to generate a swallow risk index for the subject or to generate an obstructive risk index for the subject based on a combination of a value of more than one pressure-flow variable in the pharynx and/or esophagus of the subject. In this way, swallowing motor function in the subject can be assessed by comparing the swallow risk index or obstructive risk index for the subject to a predetermined reference swallow index or predetermined reference obstructive index, respectively. Products which make use of these methods are also encompassed by the present invention.
This is a prospective, randomized, single-centre clinical study. Serum Vit D level will be assessed in all patients at baseline. Patients with Vit D level ≥30 will be excluded from the trial but included in the study and those with Vit D level \<30 will be randomized into 3 groups A, B and C. Patients with Vit D level ≥30 will be categorized into Group D. Patients belonging to Group A will be treated with low dose Vit D (2000 IU/day) according to Indian council of medical research (ICMR) guidelines. Those in Group B will be treated with high dose Vit D (60,000 IU/week) and group C will not be given any Vit D supplements. Patients belonging to Group A and B will be treated for 12 weeks in order to safely restore Vit D and achieve a steady state. In addition levocetirizine, 10 mg will be given to all patients in groups to control urticaria symptoms. All patients will be treated according to EAACI/GA2LEN/EDF guidelines after 12 weeks. All participants will also be provided with rescue prednisone use for intolerable or uncontrolled symptoms. At 6 weeks and 12 weeks, a physician assessment (physician blinded to treatment arm) will be conducted to check if patients had intolerable symptoms or took rescue prednisolone 40 mg therapy. Safety monitoring will be completed throughout the entirety of the study. Specific stopping rules and discontinuation of the study included pregnancy, a serum Vit D level higher than 100 ng/mL, or a serum calcium level higher than 11 mg/dL. Patients will be followed for 6 weeks after the study completion and thereafter data analysis will be done in 3 steps:

Step 1: Comparison of serum Vit D level in CSU patients vs. controls Step 2 : Assessment of factors associated with Vit D deficiency in urticaria patients Step 3: Effect of Vit D supplementation (group A (low dose), group B (high dose), group C(no supplementation) on urticaria severity using UAS4
A sterile pyrogen free Re<1><8><6> or Re<1><8><8> radiopharmaceutical is prepared by reducing radioactive perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO2 and free ligand. The radiopharmaceutical is obtained by a low pressure purification method. The solution is added to a separation column (12), preferably an ion exchange column, and a first portion is eluted and discarded. The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO2. This can be used as is to image and treat metastatic bone lesions. A simple kit is also disclosed.
The invention relates to a pure traditional Chinese medicine preparation prepared by lilac daphne root, cortex lycii radicis, radix scrophulariae and lithospermum. According to the preparation, a nozzle of an atomization device is utilized for directly spraying an affected gingiva lightly for administration or coating and smearing an affected tooth for administration, so that the medicine is directly absorbed by the gingiva so as to promote the blood circulation of the gingiva and eliminate the blood vessel stasis of the gingiva. Nutrition can be directly absorbed by the gingiva through active components, and the blood stasis of dental pulps is also solved readily, so that the nutrition can be directly absorbed by both of the gingiva and the dental pulps so as to eliminate the static blood stagnation in the blood vessels of the gingiva and the dental pulps and achieve double effects of promoting the blood circulation to remove the blood stasis and regulating the blood condition to alleviate pain. Therefore, the pulpitis is recovered, and the gingiva is regenerated. A loose tooth can be anew wrapped tightly by the regeneration and the expansion of an atrophied gingiva, which is beneficial to the health of periodontal tissues. Therefore, the toothache and the pulpitis are treated by the effects of promoting the blood circulation to remove the blood stasis and regulating the blood condition to alleviate the pain according to the pure traditional Chinese medicine preparation.
FIELD: medicine; particularly, stomatology. SUBSTANCE: method involves determining strength of current passing through hard tissues of erupted teeth. Common hygienic procedures are prescribed at strength of current up to 8 microamperes, while at strength of current up to 20 microamperes treatment is conducted with calcium-phosphate- and fluorine-containing preparations and then fissures are hermetically sealed. At strength of current more than 20 microamperes expansion of fissures is carried out and then, they are filled with calcium-containing paste. After it, prophylactic treatment is conducted with calcium-phosphate- and fluorine-containing preparations and molars are filled for prophylaxis. EFFECT: higher efficiency.
Many types of cancer are associated with excessive angiogenesis. Anti-angiogenic treatment is an effective strategy for treating solid cancers. This study aimed to demonstrate the inhibitory effects of (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol (MMPP) in VEGFA-induced angiogenesis. The results indicated that MMPP effectively suppressed various angiogenic processes, such as cell migration, invasion, tube formation, and sprouting of new vessels in human umbilical vein endothelial cells (HUVECs) and mouse aortic ring. The inhibitory mechanism of MMPP on angiogenesis involves targeting VEGFR2. MMPP showed high binding affinity for the VEGFR2 ATP-binding domain. Additionally, MMPP improved VEGFR2 thermal stability and inhibited VEGFR2 kinase activity, suppressing the downstream VEGFR2/AKT/ERK pathway. MMPP attenuated the activation and nuclear translocation of NF-κB, and it downregulated NF-κB target genes such as VEGFA, VEGFR2, MMP2, and MMP9. Furthermore, conditioned medium from MMPP-treated breast cancer cells effectively inhibited angiogenesis in endothelial cells. These results suggested that MMPP had great promise as a novel VEGFR2 inhibitor with potent anti-angiogenic properties for cancer treatment via VEGFR2/AKT/ERK/NF-κB signaling pathway. [BMB Reports 2024; 57(5): 244-249].
The current obstetrical practice at birth in the United States is that the umbilical cord of the infant is clamped immediately. When immediate clamping occurs, 20 to 40% of the fetal-placental blood volume is left behind in the placenta. This blood contains enough iron-rich red blood cells to meet the infant's iron needs for the first 4 to 6 months of life. Delaying cord clamping has been shown to increase early iron stores without contributing to adverse outcomes. Early iron sufficiency is essential for long term neurologic health. Iron deficiency in infancy adversely affects cognitive, motor, socio-emotional, and behavioral development. Human and animal studies have shown that inadequate iron stores in early infancy have an irreversible negative impact on the developing brain with deficits persisting even after iron levels have been restored by iron supplementation. Iron is an essential component of myelination which is critical for normal brain development and function. Myelination, which peaks during the first year of life, establishes and maintains efficient communication between the discrete regions of the brain. Abnormal myelination underlies a variety of childhood developmental disorders including conditions such as autism.

The gap is that the effect of increased iron stores from delayed cord clamping on myelination and neurodevelopment during early childhood is unknown. Our hypothesis is that placental transfusion affects myelination and early childhood development in the following ways: 1) placental transfusions lead to increased blood volume (BV) and red cell volume (RCV) at birth; 2) increased RCV results in more available iron for early body iron stores; 3) increased body iron stores provide essential iron supply for optimal myelination; 4) optimal myelination results in improved developmental and cognitive performance. We propose a randomized controlled longitudinal (birth to 24 months) trial of 128 infants to measure the effect of placental transfusion on the structure and function of the developing brain. We will use a non-invasive neuroimaging technique to measure myelin acquisition over time and to correlate the findings with iron stores and developmental outcomes. Enrolled women will be randomized at birth to the immediate cord clamping group or the delayed cord clamping group. We will assess infants for iron sufficiency and myelin deposition at 4 and 10 months and evaluate developmental outcomes at 4, 10, and 24 months. This study will help to establish a scientific basis for the timing of cord clamping with reference to brain development. The innovation of this study is in the simplicity of delaying cord clamping combined with the use of a new method of MRI that can quantify myelin deposition. This low-tech change in a clinical practice has the potential to reduce iron deficiency and improve developmental outcomes. If delayed cord clamping demonstrates protective effects for optimal development, changing practice will translate into a large cost savings improving lifetime productivity beneficial to society as a whole.
Objectives: Evaluation of the hemostatic effect of trans-arterial embolization on patients with advanced oral cavity cancer who had bleeding complications while undergoing definitive concurrent chemoradiotherapy (CCRT). Additionally, assess the effect of trans-arterial embolization on treatment response following concurrent chemoradiotherapy, as well as overall survival (OS) and progression-free survival (PFS) in the group of patients following the intervention. Method: From September 2018-June 2021, a retrospective descriptive study was conducted on 16 patients with inoperable, locally advanced oral cavity cancer who received definitive concurrent chemoradiotherapy, experienced acute bleeding complications, and received selective intravascular intervention with various embolization materials at Vietnam National Cancer Hospital. Results: After selective embolization, 16/16 patients ceased bleeding; 1 patient re-bled for the second time after 3 weeks. The average duration of chemoradiotherapy interruption due to intervention was 6.7 days. After CCRT, 15/16 (93.75%) patients achieved a response, with 9/16 (56.25%) patients achieving a complete response. The median OS was 14 months (range, 3-26 months), and the median PFS was 10 months (range, 3-20 months). There were no significant complications, particularly neurological side effects. ConclusionsTumor bleeding is a common and serious complication of CCRT treatment in patients with locally advanced oral cavity cancer. Embolization is a safe and effective method of controlling acute bleeding that has no adverse effect on the outcome of definitive concurrent chemoradiotherapy.
Type 2 diabetes is a disease with significant health consequences for the individual. Currently, new mechanisms and therapeutic approaches that may affect this disease are being sought. One of them is the association of type 2 diabetes with microbiota. Through the enteric nervous system and the gut-microbiota axis, the microbiota affects the functioning of the body. It has been proven to have a real impact on influencing glucose and lipid metabolism and insulin sensitivity. With dysbiosis, there is increased bacterial translocation through the disrupted intestinal barrier and increased inflammation in the body. In diabetes, the microbiota's composition is altered with, for example, a more abundant class of Betaproteobacteria. The consequences of these disorders are linked to mechanisms involving short-chain fatty acids, branched-chain amino acids, and bacterial lipopolysaccharide, among others. Interventions focusing on the gut microbiota are gaining traction as a promising approach to diabetes management. Studies are currently being conducted on the effects of the supply of probiotics and prebiotics, as well as fecal microbiota transplantation, on the course of diabetes. Further research will allow us to fully develop our knowledge on the subject and possibly best treat and prevent type 2 diabetes.
The present disclosure provides chimeric cytokine receptors comprising an intracellular signaling domain of interleukin-9 receptor alpha (IL 9 Ra). The present disclosure also provides modified cell(s), i.e., immune cell(s) or precursor cell(s) thereof, wherein the cell(s) are engineered to express a) interleukin-9 receptor alpha (IL 9 Ra), or a chimeric cytokine receptor disclosed herein; and b) a Chimeric Antigen Receptor (CAR). The disclosure further provides vectors (e.g., oncolytic adenoviral vectors) comprising a nucleic acid sequence encoding a cytokine, and methods of treating cancer in a subject in need thereof using the modified cells and the vectors. Also provided are modified immune cell(s) or precursor cell(s) thereof engineered to express a Chimeric Antigen Receptor (CAR), wherein expression of the hysteresis protein 5 in the cell(s) is reduced and/or eliminated. Also provided are methods and uses of the modified cells, e.g., for treating at least one sign and/or symptom of cancer. Related nucleic acids, vectors and pharmaceutical compositions are also provided.
This phase I study will enroll 25 subjects with unilateral, symptomatic ICRS Grade III or IV cartilage lesions of the knee will be candidates for this study. Baseline data will include physical examination of the knee, clinical assessment of knee pain and function using validated patient reported outcome measures (PROMs), radiographs, and MRI. Tissue from qualified donors will be used to establish allogeneic MSC banks (using current Good Manufacturing Practices (cGMPs) based on standard operating procedures), which will be tested and released for clinical use. Patients will undergo surgical debridement of their cartilage defect with harvest of the articular cartilage surrounding the defect rim. Following rapid digestion into chondrocytes and their pericellular matrix, autologous chondrons will be mixed in a 1:4 ratio with allogeneic AMSCs obtained from AMSC banks and suspended in fibrin glue for application to the debrided osteochondral defect. All patients will be clinically evaluated at 1-2 weeks, 6 weeks, 12 weeks, 24 weeks, 52 weeks, 18 moths, and 24 months post-RECLAIM for adverse events (AEs). Following completion of their respective RECLAIM treatment, each subject will be followed-up for study endpoints using a predetermined protocol, including clinical evaluation, radiography, and MRI.
Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D). The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.
Under general anesthesia, a guidewire is first inserted. Then, the Flexible Negative Pressure UAS is inserted along the guidewire to the stone site. A ureteroscope is inserted through the sheath to the stone site. The sTFL is used to fragment the stone with a power setting of 0.8J and a frequency of 12 - 20Hz. Simultaneously, the fragmented stones are removed by negative pressure suction.
NEW MATERIAL:A compound expressed by the formula (X is H or alkali metal) and S-sulfonated at least in either one of the 1st on the 7th cysteine of calcitonin. USE:A curing agent used in the treatment of osteoporosis, hypercalcemia, etc., and simulation of bony formation. PREPARATION:Calcitonin (A) is reacted with (B) sulfinic acid ion (e.g. 5- sulfothio-2-nitrobenzoic acid) to provide the monosulfonated calcitonin derivative or the monosulfonated calcitonin derivative. The product is further oxidized in the presence of an oxidizing agent (e.g. tetrathionic acid ion) to provide the disulfonated calcitonin derivative. The above-mentioned reaction is carried out in an aqueous medium preferably at pH6.0 to 10.0 and <=50 deg.C.
Anterolateral ligament(ALL) combined with anterior cruciate ligament reconstruction(ACL) has become more and more popular in recent years, as ALL could protect the ACL graft in tibial internal rotation, and prevent the ACL graft from rupture. Cottet et al. proposed a minimal invasive method with Y-figure construct of ALL, without acquiring additional graft from the patient. Their data showed significant lower graft re-rupture rate and faster return-to-sport(RTS). There are many different techniques of ACL combined ALL reconstruction. While these methods mostly are single bundle ACL combined ALL reconstruction. Previous cadaver studies told that the anterior cruciate ligament is composed of anteromedial and posterolateral bundle. It had been debated between single bundle and double bundle ACL reconstruction for years. As a result, it is meaningful to compare the clinical outcomes between ALL combined with single bundle or double bundle ACL reconstruction. Our studies included MRI image, arthrometer measurement and optical motion capture system. We hope to compare the clinical outcomes and sports function between A: single bundle ACL combined ALL reconstruction and B: double bundle ACL combined ALL reconstruction.
<P>PROBLEM TO BE SOLVED: To provide a raw material of a tooth powder that makes viscous saliva fluent to prevent formation of a film as a nutrient medium where bacteria propagate and can thereby suppress propagation of bacteria, and its manufacturing method.  <P>SOLUTION: A shell is ground into a powder. The powder is baked at 450°C for 2-4 hours. An aqueous solution of acetic acid is added to the baked powder to give a neutral aqueous solution having a pH of 6-8. Water is added to the aqueous solution, which is stirred with a mortar mixer and is refrigerated at 1-6°C for 2 days. The aqueous solution is reheated at 450°C to vaporize water in the aqueous solution to dryness to give a calcium acetate powder.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Immunological absorber comprises organic/synthetic polymer substrates covalently bonded to poly/monoclonal antibodies against peptide complement factors and sepsis mediators. Immunological absorber comprises organic/synthetic polymer substrates covalently bonded to poly/monoclonal antibodies against peptide complement factors and sepsis mediators The anaphylatoxins factors are C3a, C5a and mediators are TNF (tumor necrosis factor) and interleukins of IL1, IL6, IL8 and IL10. The sequence of C3a factor is NH 2-KCCEDGMRQNPMR-COOH, NH 2-RFSCQRRTRFISL-COOH, and NH 2-ITELRRQHARAS-COOH. The sequence of C5a factor is NH 2-QADYKDDDDKLPAE-COOH and NH 2-DDKLPAEGLDIENS-COOH. The antibodies immunoglobulin yolk (IgY), are bonded over spacer to the substrate. An independent claim is also included for production method for the above immunological absorber.
A composite tissue formed in situ is provided. The composite tissue includes a synovial joint tissue; and a barrier material adhered thereto for sealing the synovial joint tissue against synovial fluid. Also provided is a method for regenerating synovial joint tissue in situ by excluding synovial fluid therefrom. The method includes providing a synovial joint tissue having a defect; and placing a barrier material in intimate contact with the defect for sealing the defect against synovial fluid. The barrier material includes a curable protein copolymer. The method further includes curing the protein copolymer in situ. The barrier material can include a crosslinked network, or a self gelled network of repeating elastin-like and fibroin-like polymer chains.
Accurate segmentation of colorectal polyps in colonoscopy images is crucial for effective diagnosis and management of colorectal cancer (CRC). However, current deep learning-based methods primarily rely on fusing RGB information across multiple scales, leading to limitations in accurately identifying polyps due to restricted RGB domain information and challenges in feature misalignment during multi-scale aggregation. To address these limitations, we propose the Polyp Segmentation Network with Shunted Transformer (PSTNet), a novel approach that integrates both RGB and frequency domain cues present in the images. PSTNet comprises three key modules: the Frequency Characterization Attention Module (FCAM) for extracting frequency cues and capturing polyp characteristics, the Feature Supplementary Alignment Module (FSAM) for aligning semantic information and reducing misalignment noise, and the Cross Perception localization Module (CPM) for synergizing frequency cues with high-level semantics to achieve efficient polyp segmentation. Extensive experiments on challenging datasets demonstrate PSTNet's significant improvement in polyp segmentation accuracy across various metrics, consistently outperforming state-of-the-art methods. The integration of frequency domain cues and the novel architectural design of PSTNet contribute to advancing computer-assisted polyp segmentation, facilitating more accurate diagnosis and management of CRC.